Definium Therapeutics (DFTX) Change in Accured Expenses (2019 - 2026)
Definium Therapeutics (DFTX) reported Change in Accured Expenses of $3.0 million for Q1 2026, up 325.28% year-over-year from $704003.2 in Q1 2025, and up 224.38% on a QoQ basis from $923000.0 in Q4 2025.
Definium Therapeutics (DFTX) has 7 years of Change in Accured Expenses data on file, last reported at $3.0 million in Q1 2026.
- Quarterly Change in Accured Expenses rose 325.28% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.3 million (up 129.64% YoY) and the FY2025 annual result came in at $6.0 million, up 92.01% from the prior year.
- Change in Accured Expenses climbed to $3.0 million in Q1 2026 per DFTX's latest filing, from $923000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $3.8 million in Q4 2024 and bottomed at -$2.7 million in Q1 2024.
- The 5-year median for Change in Accured Expenses is $990000.0 (2024), against an average of $997470.6.
- The widest annual swing landed in 2023, when Change in Accured Expenses surged 1677.23%; it then plunged 484.5% in 2024.
- Tracing DFTX's Change in Accured Expenses over 5 years: stood at -$1.0 million in 2022, then jumped by 251.83% to $1.6 million in 2023, then jumped by 140.23% to $3.8 million in 2024, then plunged by 75.62% to $923000.0 in 2025, then surged by 224.38% to $3.0 million in 2026.
- Per Business Quant, the three latest DFTX Change in Accured Expenses figures stand at $3.0 million (Q1 2026), $923000.0 (Q4 2025), and $3.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | 2.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.99 Mn |
| Mar 31, 2026 | 2.99 Mn |
| Dec 31, 2025 | 923,000.00 |
| Dec 31, 2025 | 923,000.00 |
| Sep 30, 2025 | 3.36 Mn |
| Sep 30, 2025 | 3.36 Mn |
| Jun 30, 2025 | 3.01 Mn |
| Jun 30, 2025 | 3.01 Mn |
| Mar 31, 2025 | -1.33 Mn |
| Mar 31, 2025 | -1.33 Mn |
| Dec 31, 2024 | 3.79 Mn |
| Dec 31, 2024 | 3.79 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 990,000.00 |
| Jun 30, 2024 | 990,000.00 |
| Mar 31, 2024 | -2.70 Mn |
| Mar 31, 2024 | -2.70 Mn |
| Dec 31, 2023 | 1.58 Mn |
| Dec 31, 2023 | 1.58 Mn |
| Sep 30, 2023 | -147,000.00 |
| Sep 30, 2023 | -147,000.00 |
| Jun 30, 2023 | 3.19 Mn |
| Jun 30, 2023 | 3.19 Mn |
| Mar 31, 2023 | 703,000.00 |
| Mar 31, 2023 | 703,000.00 |
| Dec 31, 2022 | -1.04 Mn |
| Dec 31, 2022 | -1.04 Mn |
| Sep 30, 2022 | -170,000.00 |
| Sep 30, 2022 | -170,000.00 |
| Jun 30, 2022 | -202,000.00 |
| Jun 30, 2022 | -202,000.00 |
| Mar 31, 2022 | 994,000.00 |
| Mar 31, 2022 | 994,000.00 |
| Dec 31, 2021 | 7.52 Mn |
| Dec 31, 2021 | 7.52 Mn |
| Sep 30, 2021 | -5.47 Mn |
| Sep 30, 2021 | -5.47 Mn |
| Jun 30, 2021 | 1.20 Mn |
| Jun 30, 2021 | 1.20 Mn |
| Mar 31, 2021 | 1.38 Mn |
| Mar 31, 2021 | 1.38 Mn |
| Dec 31, 2019 | 744,000.00 |
| Dec 31, 2019 | 744,000.00 |